abstract: PURPOSE: The objective of this study was to assess the psychometric properties of the @entity1 Impact Scale (SIS). METHODS: Data was derived from a study assessing a community-based @entity1 rehabilitation program. @entity0 were administered the SIS and Euroqol-5D (EQ-5D-5L) on admission to the study, and at six month and 12 month follow-up. The psychometric performance of each domain of the SIS was assessed at each time point. RESULTS: A total of 164 @entity0 completed outcome measures at baseline, 108 @entity0 at six months and 37 @entity0 at 12 months. Correlation of the SIS domains with the EQ-5D-5L suggested that the dimensions of health contributing to a @entity0 's perception of health-related quality of life changes over time. CONCLUSION: The SIS performed well in a sample of @entity0 undergoing @entity1 rehabilitation in the community. Our findings suggest that the multidimensionality of the SIS may allow health professionals to track @entity0 progress and tailor rehabilitation interventions to target the dimensions of health that are most important to a @entity0 's overall health and perceived quality of life over time. Implications for Rehabilitation There is an increased need for valid and reliable measures to evaluate the outcomes of @entity0 recovering from @entity1 in the community. The @entity1 Impact Scale (SIS) measures multiple domains of health and is well-suited for use in @entity0 recovering from @entity1 in the community. There is a high level of internal consistency in the eight SIS domains with no evidence of floor effects; ceiling effects were noted for several domains. Correlation of the SIS with the Euroqol-5D suggested that the dimensions of health contributing to a @entity0 's perception of health related quality of life changes over time.

title: The @entity1 impact scale: performance as a quality of life measure in a community-based XXXX rehabilitation setting.

answer: @entity1


abstract: PURPOSE: To use a physiologically based pharmacokinetic (PBPK) modelling system to predict the serum levels achieved by two different intravenous loading doses of @entity1 . METHODS: A @entity1 pharmacokinetic model was used in the Simcyp    population-based ADME simulator, simulating 100 @entity0 age 2-10 years receiving intravenous @entity1 (18 and 20mg/kg). Visual checks were used to evaluate the predictive performance of the candidate model. RESULTS: Loading with doses of 18mg/kg, blood levels were sub-therapeutic in 22/100 (concentration at 2h post infusion (C2h) <10 g/mL), therapeutic in 62/100 (C2h 10-20 g/mL), and supra-therapeutic in 16/100 (C2h>20 g/mL). Loading with 20mg/kg, the percentages were 15, 59, and 26, respectively. Increasing from 18 to 20mg/kg increased the mean C2h from 16.0 to 17.9 g/mL, and the mean AUC from 145 to 162 g/mL/h. A C2h>30 g/mL was predicted in 4% and 8% of @entity0 in the 18 and 20mg/kg doses, with 3% predicted to have a C2h>40 g/mL following either dose. For maintenance doses, a 1st dose of 2.5 or 5mg/kg (intravenous) given at 12h (after either 18 or 20mg/kg loading) gives the highest percentages of 10-20 g/mL serum concentrations. For sub-therapeutic concentrations following intravenous loading (20mg/kg), a 1st maintenance dose (intravenous) of 10mg/kg will achieve therapeutic concentrations in 93%. CONCLUSION: Use of PBPK modelling suggests that @entity0 receiving the 20mg/kg intravenous loading dose are at slightly increased risk of supra-therapeutic blood levels. Ideally, therapeutic drug monitoring is required to monitor serum concentrations, although the dose regime suggested by the BNFc appear appropriate.

title: Comparing paediatric intravenous XXXX doses using physiologically based pharmacokinetic (PBPK) modelling software.

answer: @entity1


abstract: To further characterize the mechanism of impaired growth in @entity0 with @entity5 , we examined the serum components of the insulin-like growth factor (IGF) system in 11 @entity0 with new-onset @entity5 and followed the effect of insulinization on the IGF system longitudinally 1 day, 1 week, and 1 month after starting insulin treatment. Before insulin therapy, serum @entity2 , @entity7 , @entity6 ( @entity6 ), and @entity8 ( @entity8 ) levels were significantly decreased, whereas @entity9 and @entity3 were significantly increased in @entity1 @entity0 compared to those in an age-, sex-, and stage of puberty-matched control group. Random serum GH concentrations did not differ significantly. The alterations in the IGF system reversed with insulin therapy in a sequential manner. @entity9 fell rapidly and was comparable to control values within 24 h after insulin treatment. @entity2 rose 1 week after treatment, reaching levels comparable to those in controls and continued to rise through 1 month of treatment. @entity7 , @entity6 , and @entity8 showed a slower pattern of change, with their levels reaching control values only 1 month after the start of insulin treatment. Improvement in glycemic control, as determined by a change in hemoglobin-A1c, correlated positively with improvement in @entity2 , @entity7 , @entity6 , @entity8 , and @entity4 after 1 month of insulin therapy. These data are consistent with the hypothesis that changes in the IGF system in the insulinopenic state are similar to those during nutritional deprivation and may serve to minimize IGF's anabolic actions. The decreases in @entity2 , @entity7 , and @entity6 may in part be due to a decrease in the @entity8 /receptor. However, the observation that an increase in serum @entity2 was observed earlier than an increase in @entity8 and without a significant change in serum GH suggests a direct stimulatory effect of insulin on liver @entity2 production or reversal by insulin of some postreceptor defect in GH action independent of @entity8 .

title: Effect of insulin on the insulin-like growth factor system in @entity0 with new-onset XXXX .

answer: @entity5


abstract: To further characterize the mechanism of impaired growth in @entity0 with @entity5 , we examined the serum components of the insulin-like growth factor (IGF) system in 11 @entity0 with new-onset @entity5 and followed the effect of insulinization on the IGF system longitudinally 1 day, 1 week, and 1 month after starting insulin treatment. Before insulin therapy, serum @entity2 , @entity7 , @entity6 ( @entity6 ), and @entity8 ( @entity8 ) levels were significantly decreased, whereas @entity9 and @entity3 were significantly increased in @entity1 @entity0 compared to those in an age-, sex-, and stage of puberty-matched control group. Random serum GH concentrations did not differ significantly. The alterations in the IGF system reversed with insulin therapy in a sequential manner. @entity9 fell rapidly and was comparable to control values within 24 h after insulin treatment. @entity2 rose 1 week after treatment, reaching levels comparable to those in controls and continued to rise through 1 month of treatment. @entity7 , @entity6 , and @entity8 showed a slower pattern of change, with their levels reaching control values only 1 month after the start of insulin treatment. Improvement in glycemic control, as determined by a change in hemoglobin-A1c, correlated positively with improvement in @entity2 , @entity7 , @entity6 , @entity8 , and @entity4 after 1 month of insulin therapy. These data are consistent with the hypothesis that changes in the IGF system in the insulinopenic state are similar to those during nutritional deprivation and may serve to minimize IGF's anabolic actions. The decreases in @entity2 , @entity7 , and @entity6 may in part be due to a decrease in the @entity8 /receptor. However, the observation that an increase in serum @entity2 was observed earlier than an increase in @entity8 and without a significant change in serum GH suggests a direct stimulatory effect of insulin on liver @entity2 production or reversal by insulin of some postreceptor defect in GH action independent of @entity8 .

title: Effect of insulin on the insulin-like growth factor system in XXXX with new-onset @entity5 .

answer: @entity0


abstract: UNASSIGNED: Previously we reported that @entity7 ( @entity8 ) acts in synergy with GOS to enhance cell death in @entity0 DU145 cells. However, the underlying mechanism remains elusive. In this study, we observed that such synergistic @entity4 of GOS and @entity8 could be extended to @entity0 A375, HeLa, and PC-3 @entity1 cells. GOS and @entity8 co-treatment induced robust apoptosis as evidenced by @entity11 /-3 activation, @entity10 cleavage, and nuclear fragmentation. GOS and @entity8 also markedly decreased @entity9 protein expression. Owing to the reduction of @entity9 , @entity6 signaling was suppressed, leading to dephosphorylation of @entity12 . Consequently, @entity12 was activated and the expression of its target genes, including pro-apoptotic @entity2 and Bim, was upregulated. Supporting this, @entity12 knockdown attenuated @entity2 and Bim upregulation and apoptosis induction in GOS+ @entity8 -treated cells. Furthermore, blocking proteasome activity by @entity13 prevented the downregulation of @entity9 , dephosphorylation of @entity6 and @entity12 , and induction of apoptosis in cells co-treated with GOS and @entity8 . In @entity3 model, GOS and @entity8 combination significantly inhibited the growth of A375 @entity5 xenografts. Our findings indicate that GOS and @entity8 co-treatment induces apoptosis in @entity0 @entity1 cells by suppressing the @entity9 / @entity6 / @entity12 pathway.

title: The BH3-mimetic gossypol and noncytotoxic doses of @entity7 induce apoptosis by suppressing @entity9 / @entity6 / XXXX signaling.

answer: @entity12


abstract: UNASSIGNED: Previously we reported that @entity7 ( @entity8 ) acts in synergy with GOS to enhance cell death in @entity0 DU145 cells. However, the underlying mechanism remains elusive. In this study, we observed that such synergistic @entity4 of GOS and @entity8 could be extended to @entity0 A375, HeLa, and PC-3 @entity1 cells. GOS and @entity8 co-treatment induced robust apoptosis as evidenced by @entity11 /-3 activation, @entity10 cleavage, and nuclear fragmentation. GOS and @entity8 also markedly decreased @entity9 protein expression. Owing to the reduction of @entity9 , @entity6 signaling was suppressed, leading to dephosphorylation of @entity12 . Consequently, @entity12 was activated and the expression of its target genes, including pro-apoptotic @entity2 and Bim, was upregulated. Supporting this, @entity12 knockdown attenuated @entity2 and Bim upregulation and apoptosis induction in GOS+ @entity8 -treated cells. Furthermore, blocking proteasome activity by @entity13 prevented the downregulation of @entity9 , dephosphorylation of @entity6 and @entity12 , and induction of apoptosis in cells co-treated with GOS and @entity8 . In @entity3 model, GOS and @entity8 combination significantly inhibited the growth of A375 @entity5 xenografts. Our findings indicate that GOS and @entity8 co-treatment induces apoptosis in @entity0 @entity1 cells by suppressing the @entity9 / @entity6 / @entity12 pathway.

title: The BH3-mimetic gossypol and noncytotoxic doses of XXXX induce apoptosis by suppressing @entity9 / @entity6 / @entity12 signaling.

answer: @entity7


abstract: UNASSIGNED: Previously we reported that @entity7 ( @entity8 ) acts in synergy with GOS to enhance cell death in @entity0 DU145 cells. However, the underlying mechanism remains elusive. In this study, we observed that such synergistic @entity4 of GOS and @entity8 could be extended to @entity0 A375, HeLa, and PC-3 @entity1 cells. GOS and @entity8 co-treatment induced robust apoptosis as evidenced by @entity11 /-3 activation, @entity10 cleavage, and nuclear fragmentation. GOS and @entity8 also markedly decreased @entity9 protein expression. Owing to the reduction of @entity9 , @entity6 signaling was suppressed, leading to dephosphorylation of @entity12 . Consequently, @entity12 was activated and the expression of its target genes, including pro-apoptotic @entity2 and Bim, was upregulated. Supporting this, @entity12 knockdown attenuated @entity2 and Bim upregulation and apoptosis induction in GOS+ @entity8 -treated cells. Furthermore, blocking proteasome activity by @entity13 prevented the downregulation of @entity9 , dephosphorylation of @entity6 and @entity12 , and induction of apoptosis in cells co-treated with GOS and @entity8 . In @entity3 model, GOS and @entity8 combination significantly inhibited the growth of A375 @entity5 xenografts. Our findings indicate that GOS and @entity8 co-treatment induces apoptosis in @entity0 @entity1 cells by suppressing the @entity9 / @entity6 / @entity12 pathway.

title: The BH3-mimetic gossypol and noncytotoxic doses of @entity7 induce apoptosis by suppressing XXXX / @entity6 / @entity12 signaling.

answer: @entity9


abstract: UNASSIGNED: Previously we reported that @entity7 ( @entity8 ) acts in synergy with GOS to enhance cell death in @entity0 DU145 cells. However, the underlying mechanism remains elusive. In this study, we observed that such synergistic @entity4 of GOS and @entity8 could be extended to @entity0 A375, HeLa, and PC-3 @entity1 cells. GOS and @entity8 co-treatment induced robust apoptosis as evidenced by @entity11 /-3 activation, @entity10 cleavage, and nuclear fragmentation. GOS and @entity8 also markedly decreased @entity9 protein expression. Owing to the reduction of @entity9 , @entity6 signaling was suppressed, leading to dephosphorylation of @entity12 . Consequently, @entity12 was activated and the expression of its target genes, including pro-apoptotic @entity2 and Bim, was upregulated. Supporting this, @entity12 knockdown attenuated @entity2 and Bim upregulation and apoptosis induction in GOS+ @entity8 -treated cells. Furthermore, blocking proteasome activity by @entity13 prevented the downregulation of @entity9 , dephosphorylation of @entity6 and @entity12 , and induction of apoptosis in cells co-treated with GOS and @entity8 . In @entity3 model, GOS and @entity8 combination significantly inhibited the growth of A375 @entity5 xenografts. Our findings indicate that GOS and @entity8 co-treatment induces apoptosis in @entity0 @entity1 cells by suppressing the @entity9 / @entity6 / @entity12 pathway.

title: The BH3-mimetic gossypol and noncytotoxic doses of @entity7 induce apoptosis by suppressing @entity9 / XXXX / @entity12 signaling.

answer: @entity6


abstract: UNASSIGNED: @entity5 is a kinase inhibitor used as anticancer drug against various @entity0 @entity1 , including advanced @entity2 ( @entity2 ). @entity6 and @entity9 ( @entity10 ) are overexpressed in @entity2 and other @entity1 . Previous studies have shown that @entity10 expression modulates the response of @entity2 cells to @entity5 . However, the underlying mechanism of @entity10 activity in this context remains unclear. We show here that @entity5 inhibits both @entity6 and @entity10 in a dose-dependent manner. Silencing @entity6 reduces @entity10 level and sensitizes @entity2 cells to @entity5 . In contrast, ectopic expression of @entity6 induces @entity10 expression and cell resistance to the drug. @entity5 inhibits @entity10 expression at the transcriptional level by inhibiting the @entity6 pathway. @entity7 deletion analysis of the @entity10 gene promoter reveals that a DNA segment lying 1,500-1,600 bp upstream of the @entity10 transcription start site represents an AP-1-binding site that is critical for @entity6 modulation of gene transcription in response to @entity5 . In addition, chemical inhibitors that target @entity8 abrogate @entity6 /AP-1 binding to the endogenous @entity10 gene and reduces @entity10 transcription and protein expression. Silencing of @entity6 or @entity3 induces similar effects on gene regulation and these are reversed by ectopic expression of @entity6 . Mutations in the @entity10 promoter at the predicted @entity6 /AP-1 binding site partly abrogate @entity5 's effects on @entity10 transcription. These results indicate that @entity10 is induced by the oncoprotein @entity6 and protects @entity2 cells against @entity5 -induced cell death. The @entity6 / @entity8 / @entity10 @entity4 may thus represent a novel target for chemotherapy against @entity2 .

title: Identification of the XXXX / @entity8 / @entity9 @entity4 as a novel target of @entity5 in @entity2 cells.

answer: @entity6


abstract: UNASSIGNED: @entity5 is a kinase inhibitor used as anticancer drug against various @entity0 @entity1 , including advanced @entity2 ( @entity2 ). @entity6 and @entity9 ( @entity10 ) are overexpressed in @entity2 and other @entity1 . Previous studies have shown that @entity10 expression modulates the response of @entity2 cells to @entity5 . However, the underlying mechanism of @entity10 activity in this context remains unclear. We show here that @entity5 inhibits both @entity6 and @entity10 in a dose-dependent manner. Silencing @entity6 reduces @entity10 level and sensitizes @entity2 cells to @entity5 . In contrast, ectopic expression of @entity6 induces @entity10 expression and cell resistance to the drug. @entity5 inhibits @entity10 expression at the transcriptional level by inhibiting the @entity6 pathway. @entity7 deletion analysis of the @entity10 gene promoter reveals that a DNA segment lying 1,500-1,600 bp upstream of the @entity10 transcription start site represents an AP-1-binding site that is critical for @entity6 modulation of gene transcription in response to @entity5 . In addition, chemical inhibitors that target @entity8 abrogate @entity6 /AP-1 binding to the endogenous @entity10 gene and reduces @entity10 transcription and protein expression. Silencing of @entity6 or @entity3 induces similar effects on gene regulation and these are reversed by ectopic expression of @entity6 . Mutations in the @entity10 promoter at the predicted @entity6 /AP-1 binding site partly abrogate @entity5 's effects on @entity10 transcription. These results indicate that @entity10 is induced by the oncoprotein @entity6 and protects @entity2 cells against @entity5 -induced cell death. The @entity6 / @entity8 / @entity10 @entity4 may thus represent a novel target for chemotherapy against @entity2 .

title: Identification of the @entity6 / @entity8 / @entity9 XXXX as a novel target of @entity5 in @entity2 cells.

answer: @entity4


abstract: UNASSIGNED: @entity5 is a kinase inhibitor used as anticancer drug against various @entity0 @entity1 , including advanced @entity2 ( @entity2 ). @entity6 and @entity9 ( @entity10 ) are overexpressed in @entity2 and other @entity1 . Previous studies have shown that @entity10 expression modulates the response of @entity2 cells to @entity5 . However, the underlying mechanism of @entity10 activity in this context remains unclear. We show here that @entity5 inhibits both @entity6 and @entity10 in a dose-dependent manner. Silencing @entity6 reduces @entity10 level and sensitizes @entity2 cells to @entity5 . In contrast, ectopic expression of @entity6 induces @entity10 expression and cell resistance to the drug. @entity5 inhibits @entity10 expression at the transcriptional level by inhibiting the @entity6 pathway. @entity7 deletion analysis of the @entity10 gene promoter reveals that a DNA segment lying 1,500-1,600 bp upstream of the @entity10 transcription start site represents an AP-1-binding site that is critical for @entity6 modulation of gene transcription in response to @entity5 . In addition, chemical inhibitors that target @entity8 abrogate @entity6 /AP-1 binding to the endogenous @entity10 gene and reduces @entity10 transcription and protein expression. Silencing of @entity6 or @entity3 induces similar effects on gene regulation and these are reversed by ectopic expression of @entity6 . Mutations in the @entity10 promoter at the predicted @entity6 /AP-1 binding site partly abrogate @entity5 's effects on @entity10 transcription. These results indicate that @entity10 is induced by the oncoprotein @entity6 and protects @entity2 cells against @entity5 -induced cell death. The @entity6 / @entity8 / @entity10 @entity4 may thus represent a novel target for chemotherapy against @entity2 .

title: Identification of the @entity6 / @entity8 / @entity9 @entity4 as a novel target of XXXX in @entity2 cells.

answer: @entity5


abstract: UNASSIGNED: @entity5 is a kinase inhibitor used as anticancer drug against various @entity0 @entity1 , including advanced @entity2 ( @entity2 ). @entity6 and @entity9 ( @entity10 ) are overexpressed in @entity2 and other @entity1 . Previous studies have shown that @entity10 expression modulates the response of @entity2 cells to @entity5 . However, the underlying mechanism of @entity10 activity in this context remains unclear. We show here that @entity5 inhibits both @entity6 and @entity10 in a dose-dependent manner. Silencing @entity6 reduces @entity10 level and sensitizes @entity2 cells to @entity5 . In contrast, ectopic expression of @entity6 induces @entity10 expression and cell resistance to the drug. @entity5 inhibits @entity10 expression at the transcriptional level by inhibiting the @entity6 pathway. @entity7 deletion analysis of the @entity10 gene promoter reveals that a DNA segment lying 1,500-1,600 bp upstream of the @entity10 transcription start site represents an AP-1-binding site that is critical for @entity6 modulation of gene transcription in response to @entity5 . In addition, chemical inhibitors that target @entity8 abrogate @entity6 /AP-1 binding to the endogenous @entity10 gene and reduces @entity10 transcription and protein expression. Silencing of @entity6 or @entity3 induces similar effects on gene regulation and these are reversed by ectopic expression of @entity6 . Mutations in the @entity10 promoter at the predicted @entity6 /AP-1 binding site partly abrogate @entity5 's effects on @entity10 transcription. These results indicate that @entity10 is induced by the oncoprotein @entity6 and protects @entity2 cells against @entity5 -induced cell death. The @entity6 / @entity8 / @entity10 @entity4 may thus represent a novel target for chemotherapy against @entity2 .

title: Identification of the @entity6 / @entity8 / XXXX @entity4 as a novel target of @entity5 in @entity2 cells.

answer: @entity9


abstract: UNASSIGNED: @entity5 is a kinase inhibitor used as anticancer drug against various @entity0 @entity1 , including advanced @entity2 ( @entity2 ). @entity6 and @entity9 ( @entity10 ) are overexpressed in @entity2 and other @entity1 . Previous studies have shown that @entity10 expression modulates the response of @entity2 cells to @entity5 . However, the underlying mechanism of @entity10 activity in this context remains unclear. We show here that @entity5 inhibits both @entity6 and @entity10 in a dose-dependent manner. Silencing @entity6 reduces @entity10 level and sensitizes @entity2 cells to @entity5 . In contrast, ectopic expression of @entity6 induces @entity10 expression and cell resistance to the drug. @entity5 inhibits @entity10 expression at the transcriptional level by inhibiting the @entity6 pathway. @entity7 deletion analysis of the @entity10 gene promoter reveals that a DNA segment lying 1,500-1,600 bp upstream of the @entity10 transcription start site represents an AP-1-binding site that is critical for @entity6 modulation of gene transcription in response to @entity5 . In addition, chemical inhibitors that target @entity8 abrogate @entity6 /AP-1 binding to the endogenous @entity10 gene and reduces @entity10 transcription and protein expression. Silencing of @entity6 or @entity3 induces similar effects on gene regulation and these are reversed by ectopic expression of @entity6 . Mutations in the @entity10 promoter at the predicted @entity6 /AP-1 binding site partly abrogate @entity5 's effects on @entity10 transcription. These results indicate that @entity10 is induced by the oncoprotein @entity6 and protects @entity2 cells against @entity5 -induced cell death. The @entity6 / @entity8 / @entity10 @entity4 may thus represent a novel target for chemotherapy against @entity2 .

title: Identification of the @entity6 / @entity8 / @entity9 @entity4 as a novel target of @entity5 in XXXX cells.

answer: @entity2


abstract: UNASSIGNED: @entity5 is a kinase inhibitor used as anticancer drug against various @entity0 @entity1 , including advanced @entity2 ( @entity2 ). @entity6 and @entity9 ( @entity10 ) are overexpressed in @entity2 and other @entity1 . Previous studies have shown that @entity10 expression modulates the response of @entity2 cells to @entity5 . However, the underlying mechanism of @entity10 activity in this context remains unclear. We show here that @entity5 inhibits both @entity6 and @entity10 in a dose-dependent manner. Silencing @entity6 reduces @entity10 level and sensitizes @entity2 cells to @entity5 . In contrast, ectopic expression of @entity6 induces @entity10 expression and cell resistance to the drug. @entity5 inhibits @entity10 expression at the transcriptional level by inhibiting the @entity6 pathway. @entity7 deletion analysis of the @entity10 gene promoter reveals that a DNA segment lying 1,500-1,600 bp upstream of the @entity10 transcription start site represents an AP-1-binding site that is critical for @entity6 modulation of gene transcription in response to @entity5 . In addition, chemical inhibitors that target @entity8 abrogate @entity6 /AP-1 binding to the endogenous @entity10 gene and reduces @entity10 transcription and protein expression. Silencing of @entity6 or @entity3 induces similar effects on gene regulation and these are reversed by ectopic expression of @entity6 . Mutations in the @entity10 promoter at the predicted @entity6 /AP-1 binding site partly abrogate @entity5 's effects on @entity10 transcription. These results indicate that @entity10 is induced by the oncoprotein @entity6 and protects @entity2 cells against @entity5 -induced cell death. The @entity6 / @entity8 / @entity10 @entity4 may thus represent a novel target for chemotherapy against @entity2 .

title: Identification of the @entity6 / XXXX / @entity9 @entity4 as a novel target of @entity5 in @entity2 cells.

answer: @entity8


abstract: OBJECTIVES AND HYPOTHESIS: To establish the reliability and validity of the Dutch version of the @entity4 /Urinary Incontinence Sexual Questionnaire (PISQ-12) in @entity0 with @entity3 . METHODS: The PISQ-12 was translated into Dutch following a standardized translation process. A group of 124 @entity0 involved in a heterosexual relationship who had had symptoms of @entity2 , @entity4 for at least 3  months were eligible for inclusion. A reference group was used for assessment of discriminative ability. Data were analyzed for internal consistency, reproducibility, construct validity, responsiveness, and interpretability. An alteration was made to item 12 and was corrected for during the analysis. RESULTS: The @entity0 group comprised 70 of the 124 eligible @entity0 , and the reference group comprised 208 @entity0 from a panel representative of the Dutch female population. The Dutch PISQ-12 showed an adequate internal consistency with a Cronbach's alpha of 0.57  -  0.69, increasing with correction for item 12 to 0.69 - 0.75, for the reference and @entity0 group, respectively. Scores in the @entity0 group were lower (32.6        6.9) than in the reference group (36.3        4.8; p   =   0.0001), indicating a lower sexual function in the @entity0 group and good discriminative ability. Reproducibility was excellent with an intraclass correlation coefficient for agreement of 0.93 (0.88  -  0.96). A positive correlation was found with the Short Form-12 Health Survey (SF-12) measure representing good criterion validity. Due to the small number of @entity0 who had received treatment at the 6-month follow-up, no significant responsiveness could be established. CONCLUSIONS: This study showed that the Dutch version of the PISQ-12 has good validity and reliability. The PISQ-12 will enable Dutch physicians to evaluate @entity1 in @entity0 with @entity3 .

title: The XXXX /Urinary Incontinence Sexual Questionnaire (PISQ-12): validation of the Dutch version.

answer: @entity4


abstract: Background/Aims: Intraductal ultrasonography (IDUS) has been performed as an adjunct to endoscopic retrograde cholangiography (ERC) during radiocontrast cholangiography (RC). Radiation exposure during RC poses a health risk to both @entity0 and examiners. We evaluated the feasibility of IDUS without RC in various extrahepatic @entity1 . Methods: IDUS was performed with the insertion of an IDUS probe from the papilla of Vater to the confluent portion of the common hepatic duct without fluoroscopy. The technical success rate and procedure-related complications were evaluated retrospectively. Results: Wire-guided IDUS without RC was performed in 105 @entity0 . The mean age was 66.5 years, and 50 (47.6%) were male. The IDUS diagnoses included @entity4 (73, 69.5%), benign biliary stricture (11, 10.5%), @entity4 with @entity2 (9, 8.6%), @entity3 (5, 4.8%), @entity2 (1, 0.9%), and others (6, 5.7%). After IDUS, 66 (62.8%) underwent stone removal, 19 (18.1%) underwent biliary drainage, and 7 (6.6%) underwent brush cytology and biopsy. No significant complications such as perforation or severe @entity2 occurred. Conclusions: IDUS without RC was a feasible and safe approach in @entity0 with various extrahepatic @entity1 . We anticipate a potentially important role of IDUS in various ERC procedures because it lacks the hazards of RC.

title: Intraductal Ultrasonography without Radiocontrast Cholangiogram in XXXX with Extrahepatic Biliary Disease.

answer: @entity0


abstract: @entity4 peptides such as substance P and @entity6 have been widely studied as mediators of @entity0 transmission. The expression of neurokinin-1 and neurokinin-3 receptor messenger RNAs in the spinal cord is increased following intense nociception. The opiate ligands @entity3 and @entity2 alter behavioral responses to @entity1 -induced @entity0 and alter evoked substance P release. This study investigated whether these opiates similarly alter the expression of substance P-, @entity6 -, @entity5 - and neurokinin-3 receptor-encoding messenger RNAs in spinal systems following @entity1 -induced nociception. Expression levels of various messenger RNAs were quantitated using solution hybridization-nuclease protection assays. Six hours after hindpaw treatment, the levels of substance P-encoding preprotachykinin messenger RNA in the lumbar dorsal root ganglia and @entity6 , @entity5 and neurokinin-3 receptor messenger RNAs in the lumbar dorsal horn were increased by approximately two-fold as compared to sham-treated controls. Pretreatment with @entity2 resulted in a further increase in the nociception-induced substance P messenger RNA expression in the dorsal root ganglia; preprotachykinin messenger RNA expression was not affected by @entity3 . Nociception-induced @entity5 messenger RNA expression in the dorsal horn was blocked by @entity3 , but was not affected by @entity2 . Both @entity3 and @entity2 blocked the @entity1 -induced increases in @entity6 and neurokinin-3 receptor messenger RNA levels. Increased @entity6 messenger RNA expression may reflect increased @entity6 turnover in spinal interneurons activated by nociception. Neurokinin-3 receptor messenger RNA expression levels varied closely with, and thus may be regulated by, the levels of @entity6 messenger RNA in the same regions. The results of this study indicate that pretreatment with opiate ligands modulates the expression of @entity4 peptide and neurokinin receptor encoding mRNAs in spinal systems following a peripheral chemogenic inflammatory stimulus. Thus, endogenous opioid systems may be involved in activity-induced changes in the expression of spinal @entity4 peptides and neurokinin receptors.

title: The @entity1 -induced expression of XXXX peptide and neurokinin receptor messenger RNAs in rat sensory ganglia and spinal cord is modulated by opiate preadministration.

answer: @entity4


abstract: @entity4 peptides such as substance P and @entity6 have been widely studied as mediators of @entity0 transmission. The expression of neurokinin-1 and neurokinin-3 receptor messenger RNAs in the spinal cord is increased following intense nociception. The opiate ligands @entity3 and @entity2 alter behavioral responses to @entity1 -induced @entity0 and alter evoked substance P release. This study investigated whether these opiates similarly alter the expression of substance P-, @entity6 -, @entity5 - and neurokinin-3 receptor-encoding messenger RNAs in spinal systems following @entity1 -induced nociception. Expression levels of various messenger RNAs were quantitated using solution hybridization-nuclease protection assays. Six hours after hindpaw treatment, the levels of substance P-encoding preprotachykinin messenger RNA in the lumbar dorsal root ganglia and @entity6 , @entity5 and neurokinin-3 receptor messenger RNAs in the lumbar dorsal horn were increased by approximately two-fold as compared to sham-treated controls. Pretreatment with @entity2 resulted in a further increase in the nociception-induced substance P messenger RNA expression in the dorsal root ganglia; preprotachykinin messenger RNA expression was not affected by @entity3 . Nociception-induced @entity5 messenger RNA expression in the dorsal horn was blocked by @entity3 , but was not affected by @entity2 . Both @entity3 and @entity2 blocked the @entity1 -induced increases in @entity6 and neurokinin-3 receptor messenger RNA levels. Increased @entity6 messenger RNA expression may reflect increased @entity6 turnover in spinal interneurons activated by nociception. Neurokinin-3 receptor messenger RNA expression levels varied closely with, and thus may be regulated by, the levels of @entity6 messenger RNA in the same regions. The results of this study indicate that pretreatment with opiate ligands modulates the expression of @entity4 peptide and neurokinin receptor encoding mRNAs in spinal systems following a peripheral chemogenic inflammatory stimulus. Thus, endogenous opioid systems may be involved in activity-induced changes in the expression of spinal @entity4 peptides and neurokinin receptors.

title: The XXXX -induced expression of @entity4 peptide and neurokinin receptor messenger RNAs in rat sensory ganglia and spinal cord is modulated by opiate preadministration.

answer: @entity1


abstract: PURPOSE: Petrous apex cephalocele (PAC) is a rare lesion that has been linked to @entity1 in several case reports. The aim of this study is to document the incidence of @entity1 and PAC in consecutive brain MRI studies and study the association between these two lesions to better understand the underlying etiology of PAC. METHODS: A total of 2410 brain MRI studies were performed in our institution in the period from January 2011 to December 2011. After eliminating duplicated studies, a total of 2093 studies met our inclusion criteria. Retrospective analysis of @entity0 ' head MRI was performed by two radiologists independently to identify the presence of @entity1 and/or PAC. RESULTS: Empty sella was found in 322 (15.4  %) @entity0 . PAC was found in 111 (5.3  %) @entity0 (age range 6-81  years) of which 87 were females and 24 were males. Of all the @entity0 with PAC, 77 (69.4  %) @entity0 had associated @entity1 . Bilateral PAC was more common and seen in 77 @entity0 . CONCLUSION: PAC is associated with @entity1 , and both lesions are probably related to the same cause.

title: The association between petrous apex cephalocele and XXXX .

answer: @entity1


abstract: INTRODUCTION: @entity5 ( @entity5 ) is suspected to be the most frequent cause of @entity5 in premenopausal @entity0 . Based on the onset of @entity5 relative to the start of sexual experience, @entity5 can be divided into primary (PVD1) and secondary @entity5 (PVD2). Studies comparing these @entity5 subgroups are inconclusive as to whether differences exist in sexual and psychosocial functioning. AIM: The aim of this study was to compare the @entity3 , sexual and psychosocial functioning of a large clinical and community-based sample of premenopausal @entity0 with PVD1 and PVD2. METHODS: A total of 269 @entity0 (n   =   94 PVD1; n   =   175 PVD2) completed measures on sociodemographics, @entity3 , sexual, and psychosocial functioning. MAIN OUTCOME MEASURES: Dependent variables were the 0-10 @entity3 numerical rating scale, McGill-Melzack @entity3 Questionnaire, Female Sexual Function Index, Global Measure of Sexual Satisfaction, Beck Depression Inventory-II, Painful Intercourse Self-Efficacy Scale, @entity3 Catastrophizing Scale, State-Trait @entity2 Inventory Trait Subscale, Ambivalence over Emotional Expression Questionnaire, Hurlbert Index of Sexual Assertiveness, Experiences in Close Relationships Scale-Revised, and Dyadic Adjustment Scale-Revised. RESULTS: At first sexual relationship, @entity0 with PVD2 were significantly younger than @entity0 with PVD1 (P   <   0.01). The average relationship duration was significantly longer in @entity0 with PVD2 compared with @entity0 with PVD1 (P   <   0.01). Although @entity0 with PVD1 described a significantly longer duration of @entity3 compared with @entity0 with PVD2 (P   <   0.01), no significant subtype differences were found in @entity3 intensity during intercourse. When controlling for the sociodemographics mentioned earlier, no significant differences were found in sexual, psychological, and relational functioning between the @entity5 subgroups. Nevertheless, on average, both groups were in the clinical range of @entity4 and reported @entity1 . CONCLUSIONS: The findings show that there are no significant differences in the sexual and psychosocial profiles of @entity0 with PVD1 and PVD2. Results suggest that similar psychosocial and sex therapy interventions should be offered to both subgroups of @entity5 . Aerts L, Bergeron S, Corsini-Munt S, Steben M, and P  quet M. Are primary and secondary provoked @entity5 two different entities? A comparison of @entity3 , psychosocial, and sexual characteristics. J Sex Med **;**:**-**.

title: Are Primary and Secondary Provoked Vestibulodynia Two Different Entities? A Comparison of XXXX , Psychosocial, and Sexual Characteristics.

answer: @entity3


abstract: We report our experience with a new thermosensitive stent (Memotherm), which has been invented recently as an alternative method for treatment of @entity1 . The wall of this stent is a thermoreactive mesh made of @entity2 , which reaches its maximum force of expansion at body temperature. Its high degree of flexibility allows the Memotherm stent to fit the natural course of the prostatic urethra. This stent is available in different sizes between 2 and 8 cm to meet the demand for different lengths of prostatic urethra. Furthermore, the meshed structure of this stent allows its atraumatic removal. From April 1992 to September 1993, 54 consecutive @entity0 with @entity1 and Memotherm stents inserted. The mean @entity0 age was 76.1 years (range 61-98 years). @entity0 were considered suitable for treatment with the Memotherm stent when they presented with a poor operative risk. Mean prostatic volume was 51.9 +/- 25 ml (20-150 ml), and on average a stent measured 32.3 +/- 9.5 mm (20-70 mm). Preoperatively, only 14 @entity0 (26%) were able to void, and 40 @entity0 (74%) had had a transurethral or suprapubic catheter placed. After placement of the Memotherm stent, 53 of 54 @entity0 were able to void. In the @entity0 who were able to void preoperatively, the mean maximum flow rate increased from 4.5 ml/s to 15.8 ml/s within the first 6 months after treatment. Within the same period of time, the mean residual urine volume decreased from 194.4 ml to 11.8 ml, and the AUA 6-Symptom Score improved from 24 to 3.5 points. All differences are statistically significant (P < 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Initial experiences with the Memotherm Stent in treatment of XXXX ].

answer: @entity1


abstract: UNASSIGNED: Colonization factors (CFs) mediate early adhesion of Enterotoxigenic @entity3 (ETEC) in the small intestine. Environmental signals including bile, @entity1 , and contact with epithelial cells have previously been shown to modulate @entity5 expression in a strain dependent manner. To identify novel components modulating @entity5 surface expression, 20 components relevant to the intestinal environment were selected for evaluation. These included @entity8 , @entity6 , @entity4 , @entity11 , @entity2 sources, and cations. Effects of individual components on surface expression of the archetype @entity5 , @entity9 /I, were screened using a fractional factorial Hadamard matrix incorporating 24 growth conditions. As most CFs agglutinate erythrocytes, surface expression was evaluated by @entity10 resistant hemagglutination. Seven components, including porcine gastric @entity8 , @entity11 , @entity7 , and @entity1 were found to induce @entity9 /I surface expression in vitro in a minimal media while five others were inhibitory, including @entity0 and @entity12 . To further explore the effect of components positively influencing @entity9 /I surface expression, a response surface methodology (RSM) was designed incorporating 36 growth conditions. The optimum concentration for each component was identified, thereby generating a novel culture media, SP1, for @entity9 /I expression. CFs closely related to @entity9 /I, including CS4 and CS14 were similarly induced in SP1 media. Other epidemiologically relevant CFs were also induced when compared to the level obtained in minimal media. These results indicate that although @entity5 surface expression is complex and highly variable among strains, the @entity5 response can be predicted for closely related strains. A novel culture media inducing CFs in the CF5a group was successfully identified. In addition, @entity8 was found to positively influence @entity5 expression in strains expressing either @entity9 /I or CS1 and CS3, and may function as a common environmental cue.

title: Identification of Novel Components Influencing Colonization Factor Antigen I Expression in Enterotoxigenic XXXX .

answer: @entity3


abstract: UNASSIGNED: Background and study aims: Endoscopic ultrasound-guided choledochoduodenostomy (EUS-CDS) has gained popularity as an alternative to percutaneous biliary drainage for @entity0 in whom endoscopic retrograde cholangiopancreatography has failed. There are no previous studies comparing EUS-CDS with endoscopic transpapillary stenting (ETS) as first-line treatment for distal malignant obstruction. The aim of this study was to compare the clinical efficacy and safety of EUS-CDS and ETS as first-line treatment in @entity0 with distal malignant @entity1 . @entity0 and methods: A total of 82 @entity0 with distal malignant @entity1 underwent initial biliary drainage using self-expandable metal stents at a tertiary care university hospital. ETS was performed between June 2009 and May 2012, and EUS-CDS was performed between May 2012 and March 2014. Clinical success rates, adverse event rates, and reintervention rates were retrospectively evaluated for EUS-CDS and ETS. Results: A total of 26 @entity0 underwent EUS-CDS and 56 underwent ETS.Clinical success rates were equivalent between the groups (EUS-CDS 96.2%, ETS 98.2%; P=0.54). The mean procedure time was significantly shorter with EUS-CDS than with ETS (19.7 vs. 30.2 minutes; P<0.01). The rate of overall adverse events was not significantly different between the groups (EUS-CDS 26.9%, ETS 35.7%; P=0.46). Post-procedural @entity2 was only observed in the ETS group (0% vs. 16.1%; P=0.03). The reintervention rate at 1 year was 16.6% and 13.6% for EUS-CDS and ETS, respectively (P=0.50). Conclusions: EUS-CDS performed by expert endoscopists was associated with a short procedure time and no risk of @entity2 , and would therefore be feasible as a first-line treatment for @entity0 with distal malignant @entity1 .

title: Endoscopic ultrasound-guided choledochoduodenostomy vs. transpapillary stenting for distal XXXX .

answer: @entity1


abstract: UNASSIGNED: High-risk @entity3 remains one of the most important therapeutic challenges for pediatric oncologists. New agents or regimens are urgently needed to improve the treatment outcome of this fatal @entity1 . We examined the effect of @entity12 ( @entity12 ) inhibitors in a combination with other chemotherapeutics on a high-risk @entity3 UKF- @entity0 cell line. Treatment of UKF- @entity0 cells with DNA-damaging chemotherapeutics @entity5 or @entity9 combined with the @entity12 inhibitor @entity6 ( @entity10 ) resulted in the synergistic antitumor effect. This was associated with @entity4 -dependent induction of apoptosis. Another @entity12 inhibitor @entity11 and a derivative of @entity10 that does not exhibit @entity12 inhibitory activity, @entity8 , lacked this effect. The synergism was only induced when @entity10 was combined with cytostatics targeted to cellular DNA; @entity10 does not potentiate the @entity2 of the anticancer drug @entity7 that acts by a mechanism different from that of DNA damage. The @entity10 -mediated sensitization of UKF- @entity0 cells to @entity5 or @entity9 was dependent on the sequence of drug administration; the potentiating effect was only produced either by simultaneous treatment with these drugs or when the cells were pretreated with @entity5 or @entity9 before their exposure to @entity10 . The synergistic effects of @entity10 with @entity5 or @entity9 were associated with changes in the acetylation status of histones H3 and H4. The results of this study provide a rationale for clinical evaluation of the combination of @entity10 and @entity5 or @entity9 for treating @entity0 suffering from high-risk @entity3 .

title: The synergistic effects of DNA-damaging drugs XXXX and @entity9 with a @entity12 inhibitor @entity6 in high-risk @entity3 cells.

answer: @entity5


abstract: UNASSIGNED: High-risk @entity3 remains one of the most important therapeutic challenges for pediatric oncologists. New agents or regimens are urgently needed to improve the treatment outcome of this fatal @entity1 . We examined the effect of @entity12 ( @entity12 ) inhibitors in a combination with other chemotherapeutics on a high-risk @entity3 UKF- @entity0 cell line. Treatment of UKF- @entity0 cells with DNA-damaging chemotherapeutics @entity5 or @entity9 combined with the @entity12 inhibitor @entity6 ( @entity10 ) resulted in the synergistic antitumor effect. This was associated with @entity4 -dependent induction of apoptosis. Another @entity12 inhibitor @entity11 and a derivative of @entity10 that does not exhibit @entity12 inhibitory activity, @entity8 , lacked this effect. The synergism was only induced when @entity10 was combined with cytostatics targeted to cellular DNA; @entity10 does not potentiate the @entity2 of the anticancer drug @entity7 that acts by a mechanism different from that of DNA damage. The @entity10 -mediated sensitization of UKF- @entity0 cells to @entity5 or @entity9 was dependent on the sequence of drug administration; the potentiating effect was only produced either by simultaneous treatment with these drugs or when the cells were pretreated with @entity5 or @entity9 before their exposure to @entity10 . The synergistic effects of @entity10 with @entity5 or @entity9 were associated with changes in the acetylation status of histones H3 and H4. The results of this study provide a rationale for clinical evaluation of the combination of @entity10 and @entity5 or @entity9 for treating @entity0 suffering from high-risk @entity3 .

title: The synergistic effects of DNA-damaging drugs @entity5 and XXXX with a @entity12 inhibitor @entity6 in high-risk @entity3 cells.

answer: @entity9


abstract: UNASSIGNED: High-risk @entity3 remains one of the most important therapeutic challenges for pediatric oncologists. New agents or regimens are urgently needed to improve the treatment outcome of this fatal @entity1 . We examined the effect of @entity12 ( @entity12 ) inhibitors in a combination with other chemotherapeutics on a high-risk @entity3 UKF- @entity0 cell line. Treatment of UKF- @entity0 cells with DNA-damaging chemotherapeutics @entity5 or @entity9 combined with the @entity12 inhibitor @entity6 ( @entity10 ) resulted in the synergistic antitumor effect. This was associated with @entity4 -dependent induction of apoptosis. Another @entity12 inhibitor @entity11 and a derivative of @entity10 that does not exhibit @entity12 inhibitory activity, @entity8 , lacked this effect. The synergism was only induced when @entity10 was combined with cytostatics targeted to cellular DNA; @entity10 does not potentiate the @entity2 of the anticancer drug @entity7 that acts by a mechanism different from that of DNA damage. The @entity10 -mediated sensitization of UKF- @entity0 cells to @entity5 or @entity9 was dependent on the sequence of drug administration; the potentiating effect was only produced either by simultaneous treatment with these drugs or when the cells were pretreated with @entity5 or @entity9 before their exposure to @entity10 . The synergistic effects of @entity10 with @entity5 or @entity9 were associated with changes in the acetylation status of histones H3 and H4. The results of this study provide a rationale for clinical evaluation of the combination of @entity10 and @entity5 or @entity9 for treating @entity0 suffering from high-risk @entity3 .

title: The synergistic effects of DNA-damaging drugs @entity5 and @entity9 with a XXXX inhibitor @entity6 in high-risk @entity3 cells.

answer: @entity12


abstract: UNASSIGNED: High-risk @entity3 remains one of the most important therapeutic challenges for pediatric oncologists. New agents or regimens are urgently needed to improve the treatment outcome of this fatal @entity1 . We examined the effect of @entity12 ( @entity12 ) inhibitors in a combination with other chemotherapeutics on a high-risk @entity3 UKF- @entity0 cell line. Treatment of UKF- @entity0 cells with DNA-damaging chemotherapeutics @entity5 or @entity9 combined with the @entity12 inhibitor @entity6 ( @entity10 ) resulted in the synergistic antitumor effect. This was associated with @entity4 -dependent induction of apoptosis. Another @entity12 inhibitor @entity11 and a derivative of @entity10 that does not exhibit @entity12 inhibitory activity, @entity8 , lacked this effect. The synergism was only induced when @entity10 was combined with cytostatics targeted to cellular DNA; @entity10 does not potentiate the @entity2 of the anticancer drug @entity7 that acts by a mechanism different from that of DNA damage. The @entity10 -mediated sensitization of UKF- @entity0 cells to @entity5 or @entity9 was dependent on the sequence of drug administration; the potentiating effect was only produced either by simultaneous treatment with these drugs or when the cells were pretreated with @entity5 or @entity9 before their exposure to @entity10 . The synergistic effects of @entity10 with @entity5 or @entity9 were associated with changes in the acetylation status of histones H3 and H4. The results of this study provide a rationale for clinical evaluation of the combination of @entity10 and @entity5 or @entity9 for treating @entity0 suffering from high-risk @entity3 .

title: The synergistic effects of DNA-damaging drugs @entity5 and @entity9 with a @entity12 inhibitor XXXX in high-risk @entity3 cells.

answer: @entity6


abstract: UNASSIGNED: High-risk @entity3 remains one of the most important therapeutic challenges for pediatric oncologists. New agents or regimens are urgently needed to improve the treatment outcome of this fatal @entity1 . We examined the effect of @entity12 ( @entity12 ) inhibitors in a combination with other chemotherapeutics on a high-risk @entity3 UKF- @entity0 cell line. Treatment of UKF- @entity0 cells with DNA-damaging chemotherapeutics @entity5 or @entity9 combined with the @entity12 inhibitor @entity6 ( @entity10 ) resulted in the synergistic antitumor effect. This was associated with @entity4 -dependent induction of apoptosis. Another @entity12 inhibitor @entity11 and a derivative of @entity10 that does not exhibit @entity12 inhibitory activity, @entity8 , lacked this effect. The synergism was only induced when @entity10 was combined with cytostatics targeted to cellular DNA; @entity10 does not potentiate the @entity2 of the anticancer drug @entity7 that acts by a mechanism different from that of DNA damage. The @entity10 -mediated sensitization of UKF- @entity0 cells to @entity5 or @entity9 was dependent on the sequence of drug administration; the potentiating effect was only produced either by simultaneous treatment with these drugs or when the cells were pretreated with @entity5 or @entity9 before their exposure to @entity10 . The synergistic effects of @entity10 with @entity5 or @entity9 were associated with changes in the acetylation status of histones H3 and H4. The results of this study provide a rationale for clinical evaluation of the combination of @entity10 and @entity5 or @entity9 for treating @entity0 suffering from high-risk @entity3 .

title: The synergistic effects of DNA-damaging drugs @entity5 and @entity9 with a @entity12 inhibitor @entity6 in high-risk XXXX cells.

answer: @entity3


abstract: BACKGROUND AND OBJECTIVE: With regard to @entity2 , elevated hCG in CSF or serum has been considered to be specific for germ-cell @entity2 . Recently however, elevated hCG has also been shown to be present in cyst fluid and CSF of @entity0 with @entity5 . While germ-cell @entity2 are generally non-cystic, the aim of our study was to determine the significance of hCG in @entity7 . DESIGN: In a prospective study, hCG immunoactivity and subunits of hCG were measured in cyst fluid, CSF, and serum of @entity0 harbouring @entity7 . @entity0 AND MEASUREMENTS: hCG immunoactivity was measured in cyst fluid and serum samples of 42 @entity0 . CSF samples were available from 12 @entity0 with @entity5 . In order to fully characterize the hCG immunoactivity, we used immunoradiometric assays for total hCG activity (measuring both intact hCG and the free beta-subunit of hCG), and those specific for intact, dimeric hCG (hCG), free beta-subunit of hCG ( @entity9 ) and free alpha-subunit. Furthermore, immunostaining of @entity2 tissue was performed using monoclonal antibodies directed against the free beta-subunit of hCG. RESULTS: Total hCG immunoactivity was markedly elevated in cyst fluid of all 17 @entity5 (range 36.7-4558 IU/I; normal < 5 IU/I). Moderately elevated levels of hCG in cyst fluid were detected in three of four @entity6 , in two metastases from @entity1 and in two @entity4 . @entity9 was detected in cyst fluid from all hCG positive cysts, while specific determination of intact (dimer) hCG and alpha-subunit mostly yielded negative results. No hCG immunoactivity was found in @entity3 , @entity8 or haemangioblastomas. hCG was elevated in CSF of two @entity0 with @entity5 , but no hCG immunoactivity was detected in any serum sample. Subtle immunostaining of epithelial cell groups was shown in five of ten @entity5 . Clear immunostaining for @entity9 was also found in scattered epithelial cells of one @entity6 . CONCLUSIONS: hCG immunoactivity in @entity7 is due mainly to @entity9 . Measurement of hCG immunoactivity in cyst fluid can be helpful in the differential diagnosis of @entity7 , if surgery is restricted to cyst decompression and no histology is available. High levels suggest a @entity5 .

title: @entity0 chorionic gonadotrophin immunoactivity in XXXX .

answer: @entity2


abstract: BACKGROUND AND OBJECTIVE: With regard to @entity2 , elevated hCG in CSF or serum has been considered to be specific for germ-cell @entity2 . Recently however, elevated hCG has also been shown to be present in cyst fluid and CSF of @entity0 with @entity5 . While germ-cell @entity2 are generally non-cystic, the aim of our study was to determine the significance of hCG in @entity7 . DESIGN: In a prospective study, hCG immunoactivity and subunits of hCG were measured in cyst fluid, CSF, and serum of @entity0 harbouring @entity7 . @entity0 AND MEASUREMENTS: hCG immunoactivity was measured in cyst fluid and serum samples of 42 @entity0 . CSF samples were available from 12 @entity0 with @entity5 . In order to fully characterize the hCG immunoactivity, we used immunoradiometric assays for total hCG activity (measuring both intact hCG and the free beta-subunit of hCG), and those specific for intact, dimeric hCG (hCG), free beta-subunit of hCG ( @entity9 ) and free alpha-subunit. Furthermore, immunostaining of @entity2 tissue was performed using monoclonal antibodies directed against the free beta-subunit of hCG. RESULTS: Total hCG immunoactivity was markedly elevated in cyst fluid of all 17 @entity5 (range 36.7-4558 IU/I; normal < 5 IU/I). Moderately elevated levels of hCG in cyst fluid were detected in three of four @entity6 , in two metastases from @entity1 and in two @entity4 . @entity9 was detected in cyst fluid from all hCG positive cysts, while specific determination of intact (dimer) hCG and alpha-subunit mostly yielded negative results. No hCG immunoactivity was found in @entity3 , @entity8 or haemangioblastomas. hCG was elevated in CSF of two @entity0 with @entity5 , but no hCG immunoactivity was detected in any serum sample. Subtle immunostaining of epithelial cell groups was shown in five of ten @entity5 . Clear immunostaining for @entity9 was also found in scattered epithelial cells of one @entity6 . CONCLUSIONS: hCG immunoactivity in @entity7 is due mainly to @entity9 . Measurement of hCG immunoactivity in cyst fluid can be helpful in the differential diagnosis of @entity7 , if surgery is restricted to cyst decompression and no histology is available. High levels suggest a @entity5 .

title: XXXX chorionic gonadotrophin immunoactivity in @entity2 .

answer: @entity0


abstract: UNASSIGNED: Low-load exercise can increase serum hormones such as @entity3 ( @entity3 ) concentration in young adults when combined with blood flow restriction (BFR), but it is unclear whether walking with BFR (BFR-walk) can elevate them for older adults. Furthermore, it remained untested whether changes in these purported anabolic hormones contribute to BFR-walk-induced @entity2 . To examine the relationship between the acute and chronic effects of BFR-walk, seven @entity0 (age: 64      2  years) performed treadmill walking with (BFR-walk) and without BFR (CON-walk) at 45% of heart rate reserve for 20  min in a randomized crossover design. During BFR-walk, subjects wore 5-cm cuffs on the proximal part of the upper legs. Blood samples were taken before (PRE), immediately after (POST-1) and 15  min post (POST-2) exercise. There was a main effect of time for @entity3 (P<0  01) with levels increasing following exercise. In addition, there was a condition and time main effect for insulin; with insulin increasing to a greater degree with BFR at POST-2. Noradrenaline increased across time for both BFR-walk (P  =  0  012) and CON-walk (P<0  001); but BFR-walk induced greater elevations at POST-1 and POST-2. The change in @entity3 , insulin and @entity1 was not significantly correlated with BFR-walk-induced @entity2 . These preliminary results suggest that the BFR-walk-induced elevation in the purported anabolic hormones may not have a large impact on muscle growth.

title: Blood flow-restricted walking in older @entity0 : does the acute hormonal response associate with XXXX ?

answer: @entity2


abstract: UNASSIGNED: Low-load exercise can increase serum hormones such as @entity3 ( @entity3 ) concentration in young adults when combined with blood flow restriction (BFR), but it is unclear whether walking with BFR (BFR-walk) can elevate them for older adults. Furthermore, it remained untested whether changes in these purported anabolic hormones contribute to BFR-walk-induced @entity2 . To examine the relationship between the acute and chronic effects of BFR-walk, seven @entity0 (age: 64      2  years) performed treadmill walking with (BFR-walk) and without BFR (CON-walk) at 45% of heart rate reserve for 20  min in a randomized crossover design. During BFR-walk, subjects wore 5-cm cuffs on the proximal part of the upper legs. Blood samples were taken before (PRE), immediately after (POST-1) and 15  min post (POST-2) exercise. There was a main effect of time for @entity3 (P<0  01) with levels increasing following exercise. In addition, there was a condition and time main effect for insulin; with insulin increasing to a greater degree with BFR at POST-2. Noradrenaline increased across time for both BFR-walk (P  =  0  012) and CON-walk (P<0  001); but BFR-walk induced greater elevations at POST-1 and POST-2. The change in @entity3 , insulin and @entity1 was not significantly correlated with BFR-walk-induced @entity2 . These preliminary results suggest that the BFR-walk-induced elevation in the purported anabolic hormones may not have a large impact on muscle growth.

title: Blood flow-restricted walking in older XXXX : does the acute hormonal response associate with @entity2 ?

answer: @entity0


abstract: INTRODUCTION: Recent studies have demonstrated that ground glass opacity (GGO)-dominant @entity2 correspond to pathologically low-grade @entity3 and that @entity0 with resected @entity2 have an excellent prognosis. However, almost all of those studies were limited to @entity2 measuring  <=3.0cm. The purpose of this study was to characterize lung @entity3 >3.0cm in diameter with GGO-dominant features and evaluate the prognosis of @entity0 with such @entity2 . METHODS: One hundred and thirteen @entity0 with cT2aN0M0 @entity4 underwent surgical resection between 2005 and 2011. Twenty-five had @entity2 with a >= 50% GGO component (GGO-dominant group) and the remaining had solid-dominant @entity2 (Solid-dominant group). The clinicopathological findings and prognosis of the two groups were evaluated. RESULTS: The @entity2 in the GGO-dominant group rarely exhibited pathological invasiveness, such as lymphatic (n=1), vascular (n=0) and @entity1 (n=5) or lymph node @entity1 (n=0). On the other hand, the @entity2 in the solid-dominant group frequently exhibited pathological invasiveness, including lymphatic (n=26), vascular (n=16) and plural invasion (n=52) and lymph node @entity1 (n=18). There were significant differences in all of the characteristics between the two groups (lymphatic; p=0.0026, vascular; p=0.0214, and @entity1 ; p=0.0004, and lymph node metastases; p=0.0086, respectively). In the GGO-dominant group, 24 @entity0 were alive without recurrence, while the remaining died of another @entity2 . Recurrence occurred in 34 @entity0 in the solid-dominant group, and 16 died of the disease. The 5-year survival rate was 96% in the GGO-dominant group, compared to 71% in the solid-dominant group (p=0.0120). CONCLUSIONS: In the GGO-dominant group, the malignant potential was low and the @entity0 had a favorable prognosis after surgery, similar to the @entity0 with GGO-dominant @entity2 diagnosed as cT1a-bN0M0.

title: Does ground glass opacity-dominant feature have a prognostic significance even in clinical T2aN0M0 XXXX ?

answer: @entity4


abstract: UNASSIGNED: Tumor-derived @entity3 proteins peptide complex (HSP.PC-Tu) has been regarded as a promising antitumor agent. However, inadequate immunogenicity and low bioavailability limit the clinical uses of this agent. In a previous study, we first produced an improved @entity4 .PC  -based vaccine purified from dendritic cell (DC)- @entity2 fusion cells ( @entity4 .PC-Fc) which had increased immunogenicity due to enhanced antigenic @entity2 peptides compared to @entity4 .PC-Tu. In order to increase the bioavailability of @entity4 .PC-Fc, the peptide complex was encapsulated with nanoliposomes (NL- @entity4 .PC-Fc) in this study. After encapsulation, the @entity2 immunogenicity was observed using various assays. It was demonstrated that the NL- @entity4 .PC-Fc has acceptable stability. The in  vivo antitumor immune response was increased with regard to T-cell activation, CTL response and @entity2 therapy efficiency compared to that of @entity4 .PC-Fc. In addition, it was shown that DC maturation was improved by NL- @entity4 .PC-Fc, which added to the antitumor immunity. The results obtained for NL- @entity4 .PC-Fc, which improved immunogenicity and increases the bioavailability of @entity4 .PC, may represent superior @entity3 proteins  (HSPs)-based @entity2 vaccines. Such vaccines deserve further investigation and may provide a preclinical rationale to translate findings into early phase trials for @entity1 with @entity0 .

title: Enhanced antitumor immunity of nanoliposome-encapsulated @entity3 protein 70 peptide complex derived from XXXX fusion cells.

answer: @entity2


abstract: UNASSIGNED: Tumor-derived @entity3 proteins peptide complex (HSP.PC-Tu) has been regarded as a promising antitumor agent. However, inadequate immunogenicity and low bioavailability limit the clinical uses of this agent. In a previous study, we first produced an improved @entity4 .PC  -based vaccine purified from dendritic cell (DC)- @entity2 fusion cells ( @entity4 .PC-Fc) which had increased immunogenicity due to enhanced antigenic @entity2 peptides compared to @entity4 .PC-Tu. In order to increase the bioavailability of @entity4 .PC-Fc, the peptide complex was encapsulated with nanoliposomes (NL- @entity4 .PC-Fc) in this study. After encapsulation, the @entity2 immunogenicity was observed using various assays. It was demonstrated that the NL- @entity4 .PC-Fc has acceptable stability. The in  vivo antitumor immune response was increased with regard to T-cell activation, CTL response and @entity2 therapy efficiency compared to that of @entity4 .PC-Fc. In addition, it was shown that DC maturation was improved by NL- @entity4 .PC-Fc, which added to the antitumor immunity. The results obtained for NL- @entity4 .PC-Fc, which improved immunogenicity and increases the bioavailability of @entity4 .PC, may represent superior @entity3 proteins  (HSPs)-based @entity2 vaccines. Such vaccines deserve further investigation and may provide a preclinical rationale to translate findings into early phase trials for @entity1 with @entity0 .

title: Enhanced antitumor immunity of nanoliposome-encapsulated XXXX protein 70 peptide complex derived from @entity2 fusion cells.

answer: @entity3


abstract: The management of cervicofacial @entity2 in neonates is often complicated and may result in significant morbidity and @entity3 . A @entity1 Group (CCG) retrospective study was conducted to evaluate a multiinstitutional experience with the treatment of these extremely rare @entity1 . Twenty neonates with cervicofacial @entity2 , presenting from 1971 to 1994, were identified from nine CCG institutions. Fourteen neonates had cervical @entity2 , and six had orofacial @entity2 . There were 12 males and eight females. A diagnostic prenatal ultrasound examination was performed in six cases. Life-threatening @entity8 occurred in seven @entity0 (35%) in the early postnatal period. Two neonates died in the delivery room without ever having their airway secured. Two other @entity0 with a prenatal diagnosis survived only because tracheostomies were performed by pediatric surgeons who were in the delivery room. Three other @entity0 were orally intubated, one after sustaining hypoxic @entity7 . Eighteen @entity0 had their primary @entity1 excised. Three @entity0 required tracheostomy. After resection, two @entity0 had evidence of unilateral recurrent @entity10 , and two required prolonged @entity9 replacement. Histological examination showed eight mature and seven immature @entity2 . Four @entity0 (20%) clearly had malignant lesions. Pulmonary metastases occurred in two @entity0 and contributed to one late @entity3 at 6 months of age. The overall survival rate was 85%, and the mean follow-up period was 5 years (range, 2 months to 16 years). Twelve of 17 surviving @entity0 (70%) have had an excellent functional and cosmetic outcome. Four @entity0 have varying degrees of @entity4 and @entity6 . @entity5 at birth was believed to have contributed to these problems in two cases.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Diagnosis, management, and outcome of cervicofacial XXXX in neonates: a @entity1 Group study.

answer: @entity2


abstract: The management of cervicofacial @entity2 in neonates is often complicated and may result in significant morbidity and @entity3 . A @entity1 Group (CCG) retrospective study was conducted to evaluate a multiinstitutional experience with the treatment of these extremely rare @entity1 . Twenty neonates with cervicofacial @entity2 , presenting from 1971 to 1994, were identified from nine CCG institutions. Fourteen neonates had cervical @entity2 , and six had orofacial @entity2 . There were 12 males and eight females. A diagnostic prenatal ultrasound examination was performed in six cases. Life-threatening @entity8 occurred in seven @entity0 (35%) in the early postnatal period. Two neonates died in the delivery room without ever having their airway secured. Two other @entity0 with a prenatal diagnosis survived only because tracheostomies were performed by pediatric surgeons who were in the delivery room. Three other @entity0 were orally intubated, one after sustaining hypoxic @entity7 . Eighteen @entity0 had their primary @entity1 excised. Three @entity0 required tracheostomy. After resection, two @entity0 had evidence of unilateral recurrent @entity10 , and two required prolonged @entity9 replacement. Histological examination showed eight mature and seven immature @entity2 . Four @entity0 (20%) clearly had malignant lesions. Pulmonary metastases occurred in two @entity0 and contributed to one late @entity3 at 6 months of age. The overall survival rate was 85%, and the mean follow-up period was 5 years (range, 2 months to 16 years). Twelve of 17 surviving @entity0 (70%) have had an excellent functional and cosmetic outcome. Four @entity0 have varying degrees of @entity4 and @entity6 . @entity5 at birth was believed to have contributed to these problems in two cases.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Diagnosis, management, and outcome of cervicofacial @entity2 in neonates: a XXXX Group study.

answer: @entity1


abstract: 1. Dilatation of arterioles isolated from the @entity0 small intestine was evoked by stimulation of a submucous ganglion and the application of @entity1 , vasoactive intestinal peptide, galanin or dynorphin A. Changes in arteriole diameter and smooth muscle membrane potential were recorded simultaneously. 2. Ganglion stimulation caused vasodilatation and smooth muscle hyperpolarization that varied in both amplitude and time course from one arteriole to another. Vasodilatation could occur without hyperpolarization. 3. Vasodilatation caused by @entity1 was accompanied by a rapidly developing hyperpolarization that began to decline before the maximum vasodilator effect had developed. 4. Vasoactive intestinal peptide caused dilatation without any change in smooth muscle membrane potential. 5. Galanin and dynorphin caused dilatation and a hyperpolarization of similar time course to the dilatation. 6. In 48% of arterioles tested the dilatation appeared to be mediated solely by @entity1 . In 31% there was a cholinergic component, but no evidence for the involvement of @entity1 in the remaining 21%. When the non-cholinergic dilatation occurred without a hyperpolarization we conclude that it was due to vasoactive intestinal peptide; otherwise it may have been due to either galanin or dynorphin.

title: Vasodilatation and smooth muscle membrane potential changes in arterioles from the XXXX small intestine.

answer: @entity0


abstract: UNASSIGNED: Chromosome 14 open reading frame 166 ( @entity7 ) contributes to regulation of centrosome architecture, transcription initiation, and RNA elongation and processing. However, the role of @entity7 in @entity0 @entity2 remains unclear. This study aimed to investigate the expression and clinicopathological significance of @entity7 in @entity3 ( @entity3 ). Real-time PCR and Western blotting analyses were employed to examine @entity7 expression in immortalized primary nasopharyngeal epithelial cells (NP69), six @entity3 cell lines, three paired @entity2 samples and the adjacent noncancerous tissues from the same @entity0 , and three additional @entity2 samples. Immunohistochemistry was performed to examine @entity7 protein expression in archived @entity4 -embedded @entity2 samples from 109 @entity0 with clinicopathologically confirmed @entity3 . The association of @entity7 expression with clinicopathological features and survival outcomes was assessed. @entity7 messenger RNA and protein expression were upregulated in @entity3 cell lines and @entity0 @entity2 tissues compared to NP69 cells and noncancerous tissue samples, respectively. Immunohistochemical analyses revealed 104/109 (95.4  %) of the @entity3 tissue samples expressed @entity7 . High expression of @entity7 (cutoff score >6) was significantly associated with gender (P   =   0.016), clinical stage (P   =   0.010), T classification (P   =   0.013), N classification (P   =   0.029), distant @entity1 (P   <   0.001), vital status (P   =   0.001), and treatment method (P   =   0.028; chi-square test). High @entity7 expression was associated with significantly shorter @entity5 ( @entity5 ) and disease-free survival (DFS) than low @entity7 expression. Multivariate analysis revealed @entity7 was an independent prognostic indicator of @entity5 and DFS in all @entity0 (P   =   0.046, P   =   0.006) and was associated with poor @entity5 and DFS in the subgroups with advanced clinical stage (P   =   0.037, P   =   0.001), lymph node @entity1 (P   =   0.001, P   <   0.001), and @entity6 (P   =   0.005, P   =   0.001), respectively. @entity7 is overexpressed and may represent a novel prognostic factor in @entity3 .

title: Overexpression of chromosome 14 open reading frame 166 correlates with disease progression and poorer prognosis in @entity0 XXXX .

answer: @entity3


abstract: UNASSIGNED: Chromosome 14 open reading frame 166 ( @entity7 ) contributes to regulation of centrosome architecture, transcription initiation, and RNA elongation and processing. However, the role of @entity7 in @entity0 @entity2 remains unclear. This study aimed to investigate the expression and clinicopathological significance of @entity7 in @entity3 ( @entity3 ). Real-time PCR and Western blotting analyses were employed to examine @entity7 expression in immortalized primary nasopharyngeal epithelial cells (NP69), six @entity3 cell lines, three paired @entity2 samples and the adjacent noncancerous tissues from the same @entity0 , and three additional @entity2 samples. Immunohistochemistry was performed to examine @entity7 protein expression in archived @entity4 -embedded @entity2 samples from 109 @entity0 with clinicopathologically confirmed @entity3 . The association of @entity7 expression with clinicopathological features and survival outcomes was assessed. @entity7 messenger RNA and protein expression were upregulated in @entity3 cell lines and @entity0 @entity2 tissues compared to NP69 cells and noncancerous tissue samples, respectively. Immunohistochemical analyses revealed 104/109 (95.4  %) of the @entity3 tissue samples expressed @entity7 . High expression of @entity7 (cutoff score >6) was significantly associated with gender (P   =   0.016), clinical stage (P   =   0.010), T classification (P   =   0.013), N classification (P   =   0.029), distant @entity1 (P   <   0.001), vital status (P   =   0.001), and treatment method (P   =   0.028; chi-square test). High @entity7 expression was associated with significantly shorter @entity5 ( @entity5 ) and disease-free survival (DFS) than low @entity7 expression. Multivariate analysis revealed @entity7 was an independent prognostic indicator of @entity5 and DFS in all @entity0 (P   =   0.046, P   =   0.006) and was associated with poor @entity5 and DFS in the subgroups with advanced clinical stage (P   =   0.037, P   =   0.001), lymph node @entity1 (P   =   0.001, P   <   0.001), and @entity6 (P   =   0.005, P   =   0.001), respectively. @entity7 is overexpressed and may represent a novel prognostic factor in @entity3 .

title: Overexpression of chromosome 14 open reading frame 166 correlates with disease progression and poorer prognosis in XXXX @entity3 .

answer: @entity0


abstract: UNASSIGNED: @entity3 is a rare manifestation of chronic GvHD (cGvHD). No risk factors or laboratory changes associated with this syndrome have been recognized to date, and outcomes have not been described in a large series. We searched our institutional database for @entity0 undergoing allogeneic hematopoietic cell transplant identified as having @entity3 or @entity2 . Laboratory studies from prior to diagnosis, at diagnosis and post diagnosis of @entity3 , as well as outcomes from invasive procedures were included. Twenty @entity0 met criteria for cGvHD-associated @entity3 , and all but three @entity0 had a prior diagnosis of cGvHD. Fifteen were male, and the complication occurred in the setting of immunosuppressant taper in 12 cases. Ten @entity0 required invasive interventions, including pericardial window or stripping. A significant increase in blood monocytes and decrease in serum albumin were identified at diagnosis compared with pre-diagnosis. Out of 20 @entity0 , 17 were treated with @entity1 , with 12 demonstrating a complete response. These data suggest that cGvHD-associated @entity3 occurs mainly in the setting of treated as opposed to de novo cGvHD and biomarkers associated with the syndrome include a decrease in albumin and an increase in absolute monocyte count. Outcome data from larger series are required to better understand the optimal management of this rare complication.Bone Marrow Transplantation advance online publication, 11 May 2015; doi:10.1038/bmt.2015.105.

title: Chronic GvHD-associated @entity3 and XXXX .

answer: @entity2


abstract: UNASSIGNED: @entity3 is a rare manifestation of chronic GvHD (cGvHD). No risk factors or laboratory changes associated with this syndrome have been recognized to date, and outcomes have not been described in a large series. We searched our institutional database for @entity0 undergoing allogeneic hematopoietic cell transplant identified as having @entity3 or @entity2 . Laboratory studies from prior to diagnosis, at diagnosis and post diagnosis of @entity3 , as well as outcomes from invasive procedures were included. Twenty @entity0 met criteria for cGvHD-associated @entity3 , and all but three @entity0 had a prior diagnosis of cGvHD. Fifteen were male, and the complication occurred in the setting of immunosuppressant taper in 12 cases. Ten @entity0 required invasive interventions, including pericardial window or stripping. A significant increase in blood monocytes and decrease in serum albumin were identified at diagnosis compared with pre-diagnosis. Out of 20 @entity0 , 17 were treated with @entity1 , with 12 demonstrating a complete response. These data suggest that cGvHD-associated @entity3 occurs mainly in the setting of treated as opposed to de novo cGvHD and biomarkers associated with the syndrome include a decrease in albumin and an increase in absolute monocyte count. Outcome data from larger series are required to better understand the optimal management of this rare complication.Bone Marrow Transplantation advance online publication, 11 May 2015; doi:10.1038/bmt.2015.105.

title: Chronic GvHD-associated XXXX and @entity2 .

answer: @entity3


abstract: @entity0 basophils are an accessible @entity0 of the @entity0 @entity1 . There is natural variation in various functional endpoints and in signaling molecule expression but there has been only a limited effort to place this information in the context of mRNA expression profiles. This study examined the hypothesis that unique mRNA signatures could be identified during the response of @entity0 basophils to several known forms of stimulation. Highly purified @entity0 basophils were cultured in vitro and exposed to @entity4 , @entity2 , NGF, @entity6 , @entity3 , anti-IgE Ab, or @entity5 and the mRNA profiles examined by microarrays. The response to @entity4 and anti-IgE Ab were examined on 2-3 time frames and the response to @entity4 examined at several concentrations. In addition, the mRNA signatures of 3 different potential phenotypes were examined. These included basophils with the so-called non-releaser phenotype, and basophils from atopic and non-atopic subjects. Given the role of @entity4 in basophil maturation and the known profound effects on mature basophil function, it was not surprising that @entity4 showed the greatest influence on the basophil transcriptome. However, it also became apparent that the act of isolating and culturing basophils was sufficient to induce a large number of changes in the transcriptome, despite high viability and recovery. These "culture-effect" changes dominated the changes in mRNA profiles induced by other stimuli. Unique signatures for anti-IgE antibody and @entity6 could be identified although the number of gene transcripts (6-30) that were unique to these two stimuli was very limited. There were no apparent unique profiles for @entity2 , NGF, @entity3 or @entity5 . Therefore, a potential tool for screening basophil phenotypes was limited to changes that could be induced by @entity4 ), @entity6 and anti-IgE Ab.

title: Expression profiling of XXXX basophils: modulation by cytokines and secretagogues.

answer: @entity0


abstract: UNASSIGNED: @entity4 ( @entity4 ) is the most common @entity3 ( @entity3 ) with @entity1 and @entity2 recurrence resulting in 90  % of @entity2 associated mortality. @entity5 , an inflammatory biomarker, has been shown to play a significant role in tumorigenesis of @entity4 . To study the expression of @entity5 in @entity4 by immunohistochemistry and investigate its association with the clinicopathological parameters including @entity0 survival. A cross sectional study was carried out in 75 histologically confirmed cases of @entity4 . @entity5 expression was evaluated by indirect streptavidin biotin method. The expression was semi-quantitatively assessed using established criteria. The expression profile of @entity5 was correlated with the clinicopathological details like @entity2 size, regional lymphnode @entity1 , distant @entity1 , clinical stage, local recurrence of @entity2 , histological grade, and survival of @entity0 . Chi square and Kaplan Meier statistical tests were applied for assessing this association. @entity5 expression was absent in normal oral mucosa. Over expression of @entity5 was seen in 58 out of 75 specimens of @entity4 . Overexpression of @entity5 was significantly associated with the lymphnode involvement, histological grade, local recurrence of @entity2 and @entity0 survival. @entity5 expression represents an important biomarker of prognostic significance that may be used to identify a subset of @entity0 at high risk and to predict @entity0 survival.

title: Cyclooxygenase-2 - An Imperative Prognostic Biomarker in XXXX - An Immunohistochemical Study.

answer: @entity4


abstract: UNASSIGNED: Background: The most common long-term complication of tracheotomy is the benign @entity2 of the @entity1 , which is described for up to 20% of the cases. Typically, the @entity2 occurs after decannulation in the context of secondary wound healing. This study examined whether the closure of the tracheostomy by surgical procedure reduces @entity2 . Method: With the help of our clinical database a retrospective analysis of 401 surgical tracheotomies was performed. Variables that were recorded were the indication for tracheotomy, the clinical course and complications occurred. Results: 155 @entity0 were successfully decannulated. In 92 of these @entity0 the tracheostomy was closed by a surgical procedure, in 63 cases the closure occurred spontaneously by wound healing. After decannulation 3% (n=3) of the surgically closed and 22% (n=14) of the spontaneously closed tracheostomies developed a symptomatic @entity3 (p<0.001). Conclusion: Secondary wound healing of the tracheostomy often leads to symptomatic @entity3 . The incidence of symptomatic @entity3 was significantly reduced applying closure of the tracheostomy by surgical procedure.

title: [Reduction of Tracheotomy Associated XXXX by Surgical Closure of the Tracheostomy].

answer: @entity3


abstract: PURPOSE: Bone morphogenetic proteins (BMPs) are pleiotropic growth factors. This paper investigates the connection between the expression pattern of BMPs in kidney allograft tissue versus the cause of allograft dysfunction. METHODS: The expression pattern of @entity2 , @entity5 , @entity3 and @entity4 in 50 kidney allografts obtained by transplant nephrectomy is investigated. Immunohistochemical staining is semiquantitatively evaluated for intensity to identify the expression pattern of BMPs in normal and allograft kidney tissues. RESULTS: The expression of @entity5 is unique between different tubular cell types in grafts without signs of @entity0 . This effect is not found in specimens with high grades of @entity0 and @entity1 (IFTA). In samples with IFTA grades II and III, the @entity4 expression is reduced in a significant fraction of specimens relative to those without signs of IFTA. The expression pattern of @entity3 indicates that its activation may be triggered by the act of transplantation and subsequent reperfusion injury. The expression of @entity2 is strong in all types of tubular epithelial cells and does not differ between the compared allografts and control kidney specimens. CONCLUSION: The intensity and expression pattern of @entity5 , @entity3 and @entity4 in transplanted kidney tissue are found to be dependent upon the length of the transplanted period, the clinical indication for transplant nephrectomy and signs of IFTA in kidney tissue.

title: Expression of bone morphogenetic proteins 4, 6 and 7 is downregulated in kidney allografts with XXXX and @entity1 .

answer: @entity0


abstract: PURPOSE: Bone morphogenetic proteins (BMPs) are pleiotropic growth factors. This paper investigates the connection between the expression pattern of BMPs in kidney allograft tissue versus the cause of allograft dysfunction. METHODS: The expression pattern of @entity2 , @entity5 , @entity3 and @entity4 in 50 kidney allografts obtained by transplant nephrectomy is investigated. Immunohistochemical staining is semiquantitatively evaluated for intensity to identify the expression pattern of BMPs in normal and allograft kidney tissues. RESULTS: The expression of @entity5 is unique between different tubular cell types in grafts without signs of @entity0 . This effect is not found in specimens with high grades of @entity0 and @entity1 (IFTA). In samples with IFTA grades II and III, the @entity4 expression is reduced in a significant fraction of specimens relative to those without signs of IFTA. The expression pattern of @entity3 indicates that its activation may be triggered by the act of transplantation and subsequent reperfusion injury. The expression of @entity2 is strong in all types of tubular epithelial cells and does not differ between the compared allografts and control kidney specimens. CONCLUSION: The intensity and expression pattern of @entity5 , @entity3 and @entity4 in transplanted kidney tissue are found to be dependent upon the length of the transplanted period, the clinical indication for transplant nephrectomy and signs of IFTA in kidney tissue.

title: Expression of bone morphogenetic proteins 4, 6 and 7 is downregulated in kidney allografts with @entity0 and XXXX .

answer: @entity1


abstract: Effects of @entity2 ( @entity0 ), the neurotransmitter released by photoreceptors, on isolated cat bipolar cells were examined. Membrane currents of bipolar cells were recorded by the patch-clamp technique in a conventional whole-cell recording configuration using pipettes containing 1 mM @entity1 , which has been known to activate a cationic current sensitive to @entity0 in ON-type bipolar cells. ON-type bipolar cells (depolarized by light in in situ) and OFF-type bipolar cells (hyperpolarized by light) were identified by their response polarity to @entity0 . When the whole-cell configuration was established, ON-type bipolar cells showed a steady inward current which was suppressed by @entity0 , consistent with the response polarity observed in in situ recordings. In contrast, OFF-type cells did not show a steady current during the recordings. However, they responded to @entity0 with an increase in cationic conductance. Among recorded cells, rod-driven bipolar cells were identified by their immunoreactivity to anti-protein kinase C (PKC-IR) antibody. Examination of PKC-IR revealed that ON-type bipolar cells included both rod- and cone-driven bipolar cells, while OFF-type cells were all cone-driven bipolar cells. The @entity1 -activated current observed in ON-type cells was accompanied by a change in the current fluctuation due to the opening and closing of underlying channels. Fluctuation analysis gave a unitary conductance value of 13 pS. In half of the cells examined, maximum open probability reached almost 100%. The @entity1 -activated channel in bipolar cells seems novel, fundamentally different from those found in photoreceptor cells or olfactory receptor cells.

title: XXXX -induced responses and @entity1 -activated channels in three subtypes of retinal bipolar cells dissociated from the cat.

answer: @entity2


abstract: Effects of @entity2 ( @entity0 ), the neurotransmitter released by photoreceptors, on isolated cat bipolar cells were examined. Membrane currents of bipolar cells were recorded by the patch-clamp technique in a conventional whole-cell recording configuration using pipettes containing 1 mM @entity1 , which has been known to activate a cationic current sensitive to @entity0 in ON-type bipolar cells. ON-type bipolar cells (depolarized by light in in situ) and OFF-type bipolar cells (hyperpolarized by light) were identified by their response polarity to @entity0 . When the whole-cell configuration was established, ON-type bipolar cells showed a steady inward current which was suppressed by @entity0 , consistent with the response polarity observed in in situ recordings. In contrast, OFF-type cells did not show a steady current during the recordings. However, they responded to @entity0 with an increase in cationic conductance. Among recorded cells, rod-driven bipolar cells were identified by their immunoreactivity to anti-protein kinase C (PKC-IR) antibody. Examination of PKC-IR revealed that ON-type bipolar cells included both rod- and cone-driven bipolar cells, while OFF-type cells were all cone-driven bipolar cells. The @entity1 -activated current observed in ON-type cells was accompanied by a change in the current fluctuation due to the opening and closing of underlying channels. Fluctuation analysis gave a unitary conductance value of 13 pS. In half of the cells examined, maximum open probability reached almost 100%. The @entity1 -activated channel in bipolar cells seems novel, fundamentally different from those found in photoreceptor cells or olfactory receptor cells.

title: @entity2 -induced responses and XXXX -activated channels in three subtypes of retinal bipolar cells dissociated from the cat.

answer: @entity1


abstract: Telehealth has become a very important tool that allows the monitoring of @entity1 @entity0 in a home environment. However, little is known about the effect that such monitoring systems have on @entity0 ' compliance, evolution and self-care behaviour. In particular, the effect that the selected user interface has on these factors is unknown. This study aims to investigate this, and to determine some practicalities that must be considered when designing and implementing a telehealth programme for @entity1 . To achieve this, daily measurements of blood pressure, pulse, SpO2 and weight were collected from 534 @entity0 suffering from @entity1 . In addition, they were asked to fill in the European @entity1 self-care behaviour scale questionnaire and the EQ-5D quality of life questionnaire, before and after the monitoring period. Two telehealth systems were used, the Motiva platform provided by Philips and the standalone unit provided by Docobo, the Doc@Home system. Significant differences were found between both systems concerning the compliance and adherence of @entity0 . Moreover, a general, positive effect of telehealth was identified due to the fact that @entity0 showed an increased self-awareness when managing their condition. These findings are supported by behavioural changes and a better understanding of @entity1 from the @entity0 ' perspective.

title: Telehealth on XXXX : results of the Recap project.

answer: @entity1


abstract: INTRODUCTION: The national database of @entity5 ( @entity5 ) in Thailand is limited in terms of the characteristics of the demographics, outcome, and prognostic factors. MATERIALS AND METHODS: We retrospectively explored national data in Thailand for reimbursement of all adult @entity0 with @entity5 admitted in the fiscal year 2004-2012. @entity0 with @entity5 were diagnosed and searched based on ICD 10 (G41) from the national database of the Universal Health Coverage Insurance office. RESULTS: There were 12,367 @entity0 with @entity5 . The average age was 48.14years, and 8119 @entity0 were males (65.7%). At discharge, 75.2% of @entity0 were improved, while 16.4% were not improved, and in-hospital mortality rate was 8.4%. The first three most common comorbid conditions were @entity4 (1790 @entity0 , 14.5%), @entity1 (1064 @entity0 , 8.6%), and previous @entity3 (819 @entity0 , 6.6%). The common complications were @entity7 (3990 @entity0 , 32.3%), @entity2 (1201 @entity0 , 9.7%) and @entity6 (876 @entity0 , 7.1%). The mean (SD) hospital stay was 5.48 (11.44) days. @entity0 with @entity5 with age over 60years, female @entity0 , and @entity0 at primary care hospitals had higher proportions of poor outcomes at 36.1%, 39.6%, and 40.9%. Out of 11 comorbid conditions, six of them were significantly associated with poor outcomes. Additionally, 5 complications and two procedures were significant factors of poor outcomes. CONCLUSIONS: Factors associated with poor outcome in admitted @entity0 with @entity5 by the national data were age, gender, hospital level, comorbid conditions, complications of @entity5 , and procedural intervention. This article is part of a Special Issue entitled " @entity5 ".

title: Incidences and outcomes of XXXX : A 9-year longitudinal national study.

answer: @entity5


abstract: UNASSIGNED: @entity9 ( @entity6 ) is an active compound extracted from the traditional Chinese medicinal herb Chuanxiong. Previously, we have shown that @entity6 induces @entity0 SH-SY5Y @entity2 cell differentiation toward the neuronal phenotype by targeting topoisomeraseIIb (TopoIIb), a protein implicated in neural development. In the present study, we aimed to elucidate whether the transcriptional factors @entity5 ( @entity5 ) and nuclear factor Y (NF-Y), in addition to the upstream signaling pathways @entity4 and @entity7 / @entity3 , are involved in modulating TopoIIb expression in the neuronal differentiation process. We demonstrated that SH-SY5Y cells treated with @entity6 (80 M) terminally differentiated into neurons, characterized by increased neuronal markers, tubulin bIII and @entity8 ( @entity8 ), and increased neurite outgrowth, with no negative effect on cell survival. @entity6 also increased the expression of TopoIIb, which was accompanied by increased expression of @entity5 in the differentiated neuron-like cells, whereas NF-Y protein levels remained unchanged following the differentiation progression. We also found that the phosphorylation level of @entity3 , but not @entity4 , was significantly increased as a result of @entity6 stimulation. Furthermore, as established by chromatin immunoprecipitation (ChIP) assay, activation of the @entity7 / @entity3 pathway increased @entity5 binding to the promoter of the TopoIIb gene. Blockage of @entity7 / @entity3 was shown to lead to subsequent inhibition of TopoIIb expression and neuronal differentiation. Collectively, the results indicate that the @entity7 / @entity3 / @entity5 /TopoIIb signaling pathway is necessary for @entity6 -induced neuronal differentiation. Our findings offer mechanistic insights into understanding the upstream regulation of TopoIIb in neuronal differentiation, and suggest potential applications of @entity6 both in neuroscience research and clinical practice to treat relevant @entity1 .

title: @entity9 induces SH-SY5Y cell differentiation toward the neuronal phenotype through activation of the @entity7 / @entity3 / XXXX /TopoIIb pathway.

answer: @entity5


abstract: UNASSIGNED: @entity9 ( @entity6 ) is an active compound extracted from the traditional Chinese medicinal herb Chuanxiong. Previously, we have shown that @entity6 induces @entity0 SH-SY5Y @entity2 cell differentiation toward the neuronal phenotype by targeting topoisomeraseIIb (TopoIIb), a protein implicated in neural development. In the present study, we aimed to elucidate whether the transcriptional factors @entity5 ( @entity5 ) and nuclear factor Y (NF-Y), in addition to the upstream signaling pathways @entity4 and @entity7 / @entity3 , are involved in modulating TopoIIb expression in the neuronal differentiation process. We demonstrated that SH-SY5Y cells treated with @entity6 (80 M) terminally differentiated into neurons, characterized by increased neuronal markers, tubulin bIII and @entity8 ( @entity8 ), and increased neurite outgrowth, with no negative effect on cell survival. @entity6 also increased the expression of TopoIIb, which was accompanied by increased expression of @entity5 in the differentiated neuron-like cells, whereas NF-Y protein levels remained unchanged following the differentiation progression. We also found that the phosphorylation level of @entity3 , but not @entity4 , was significantly increased as a result of @entity6 stimulation. Furthermore, as established by chromatin immunoprecipitation (ChIP) assay, activation of the @entity7 / @entity3 pathway increased @entity5 binding to the promoter of the TopoIIb gene. Blockage of @entity7 / @entity3 was shown to lead to subsequent inhibition of TopoIIb expression and neuronal differentiation. Collectively, the results indicate that the @entity7 / @entity3 / @entity5 /TopoIIb signaling pathway is necessary for @entity6 -induced neuronal differentiation. Our findings offer mechanistic insights into understanding the upstream regulation of TopoIIb in neuronal differentiation, and suggest potential applications of @entity6 both in neuroscience research and clinical practice to treat relevant @entity1 .

title: XXXX induces SH-SY5Y cell differentiation toward the neuronal phenotype through activation of the @entity7 / @entity3 / @entity5 /TopoIIb pathway.

answer: @entity9